nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—EGFR—ovarian cancer	0.338	0.767	CbGaD
Lidocaine—EGFR—Docetaxel—ovarian cancer	0.121	0.334	CbGbCtD
Lidocaine—ABCB1—ovarian cancer	0.103	0.233	CbGaD
Lidocaine—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0205	0.0563	CbGbCtD
Lidocaine—CYP3A7—Paclitaxel—ovarian cancer	0.0205	0.0563	CbGbCtD
Lidocaine—ABCB1—Topotecan—ovarian cancer	0.0202	0.0555	CbGbCtD
Lidocaine—CYP3A5—Paclitaxel—ovarian cancer	0.0154	0.0422	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0148	0.0407	CbGbCtD
Lidocaine—CYP3A7—Docetaxel—ovarian cancer	0.0148	0.0407	CbGbCtD
Lidocaine—CYP2C8—Paclitaxel—ovarian cancer	0.0148	0.0406	CbGbCtD
Lidocaine—ABCB1—Vinorelbine—ovarian cancer	0.0142	0.0391	CbGbCtD
Lidocaine—CYP2D6—Vinorelbine—ovarian cancer	0.0134	0.0369	CbGbCtD
Lidocaine—CYP3A4—Topotecan—ovarian cancer	0.0121	0.0333	CbGbCtD
Lidocaine—CYP3A5—Docetaxel—ovarian cancer	0.0111	0.0305	CbGbCtD
Lidocaine—CYP2B6—Doxorubicin—ovarian cancer	0.0105	0.0289	CbGbCtD
Lidocaine—CYP2C9—Paclitaxel—ovarian cancer	0.0103	0.0283	CbGbCtD
Lidocaine—ABCB1—Paclitaxel—ovarian cancer	0.00999	0.0275	CbGbCtD
Lidocaine—CYP3A4—Vinorelbine—ovarian cancer	0.00852	0.0234	CbGbCtD
Lidocaine—ABCB1—Docetaxel—ovarian cancer	0.00722	0.0199	CbGbCtD
Lidocaine—CYP3A4—Paclitaxel—ovarian cancer	0.00599	0.0165	CbGbCtD
Lidocaine—ABCB1—Doxorubicin—ovarian cancer	0.00539	0.0148	CbGbCtD
Lidocaine—CYP2D6—Doxorubicin—ovarian cancer	0.00507	0.014	CbGbCtD
Lidocaine—CYP3A4—Docetaxel—ovarian cancer	0.00433	0.0119	CbGbCtD
Lidocaine—CYP3A4—Doxorubicin—ovarian cancer	0.00323	0.00888	CbGbCtD
Lidocaine—EGFR—uterine cervix—ovarian cancer	0.00104	0.0576	CbGeAlD
Lidocaine—CYP2C18—uterine cervix—ovarian cancer	0.000897	0.0498	CbGeAlD
Lidocaine—EGFR—uterus—ovarian cancer	0.000865	0.048	CbGeAlD
Lidocaine—EGFR—female gonad—ovarian cancer	0.000708	0.0393	CbGeAlD
Lidocaine—EGFR—testis—ovarian cancer	0.000628	0.0349	CbGeAlD
Lidocaine—CYP2C18—vagina—ovarian cancer	0.000608	0.0337	CbGeAlD
Lidocaine—SCN3A—decidua—ovarian cancer	0.000565	0.0314	CbGeAlD
Lidocaine—SCN9A—testis—ovarian cancer	0.000517	0.0287	CbGeAlD
Lidocaine—SCN4A—testis—ovarian cancer	0.000461	0.0256	CbGeAlD
Lidocaine—SCN2A—vagina—ovarian cancer	0.000457	0.0254	CbGeAlD
Lidocaine—EGFR—lymph node—ovarian cancer	0.000455	0.0253	CbGeAlD
Lidocaine—SCN3A—female reproductive system—ovarian cancer	0.000444	0.0247	CbGeAlD
Lidocaine—SLC22A5—myometrium—ovarian cancer	0.000442	0.0245	CbGeAlD
Lidocaine—SCN3A—bone marrow—ovarian cancer	0.00042	0.0233	CbGeAlD
Lidocaine—SCN3A—vagina—ovarian cancer	0.000402	0.0223	CbGeAlD
Lidocaine—CYP2A6—vagina—ovarian cancer	0.000402	0.0223	CbGeAlD
Lidocaine—SCN5A—vagina—ovarian cancer	0.000401	0.0223	CbGeAlD
Lidocaine—SCN9A—lymph node—ovarian cancer	0.000375	0.0208	CbGeAlD
Lidocaine—SCN3A—testis—ovarian cancer	0.000359	0.0199	CbGeAlD
Lidocaine—SLC22A5—uterine cervix—ovarian cancer	0.000344	0.0191	CbGeAlD
Lidocaine—SLC22A5—endometrium—ovarian cancer	0.000311	0.0173	CbGeAlD
Lidocaine—CYP2C8—endometrium—ovarian cancer	0.000301	0.0167	CbGeAlD
Lidocaine—CYP3A5—uterine cervix—ovarian cancer	0.0003	0.0167	CbGeAlD
Lidocaine—SCN10A—lymph node—ovarian cancer	0.000285	0.0158	CbGeAlD
Lidocaine—SCN3A—lymph node—ovarian cancer	0.00026	0.0144	CbGeAlD
Lidocaine—SLC22A5—female reproductive system—ovarian cancer	0.000258	0.0143	CbGeAlD
Lidocaine—CYP2B6—gonad—ovarian cancer	0.00025	0.0139	CbGeAlD
Lidocaine—CYP2C8—female reproductive system—ovarian cancer	0.000249	0.0138	CbGeAlD
Lidocaine—SLC22A5—female gonad—ovarian cancer	0.000234	0.013	CbGeAlD
Lidocaine—SLC22A5—vagina—ovarian cancer	0.000233	0.0129	CbGeAlD
Lidocaine—CYP2C8—vagina—ovarian cancer	0.000225	0.0125	CbGeAlD
Lidocaine—CYP2B6—female reproductive system—ovarian cancer	0.000224	0.0124	CbGeAlD
Lidocaine—CYP2C9—female reproductive system—ovarian cancer	0.000221	0.0123	CbGeAlD
Lidocaine—SLC22A5—testis—ovarian cancer	0.000208	0.0115	CbGeAlD
Lidocaine—ABCB1—myometrium—ovarian cancer	0.000205	0.0114	CbGeAlD
Lidocaine—CYP3A5—female gonad—ovarian cancer	0.000205	0.0114	CbGeAlD
Lidocaine—Pain—Topotecan—ovarian cancer	0.000204	0.00188	CcSEcCtD
Lidocaine—Ventricular tachycardia—Doxorubicin—ovarian cancer	0.000204	0.00188	CcSEcCtD
Lidocaine—CYP3A5—vagina—ovarian cancer	0.000204	0.0113	CbGeAlD
Lidocaine—CYP2B6—vagina—ovarian cancer	0.000202	0.0112	CbGeAlD
Lidocaine—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000202	0.00186	CcSEcCtD
Lidocaine—Bronchospasm—Docetaxel—ovarian cancer	0.000201	0.00186	CcSEcCtD
Lidocaine—Dermatitis contact—Doxorubicin—ovarian cancer	0.000201	0.00186	CcSEcCtD
Lidocaine—CYP2C8—testis—ovarian cancer	0.000201	0.0112	CbGeAlD
Lidocaine—Coma—Epirubicin—ovarian cancer	0.000201	0.00186	CcSEcCtD
Lidocaine—Nervous system disorder—Vinorelbine—ovarian cancer	0.0002	0.00185	CcSEcCtD
Lidocaine—Pain—Melphalan—ovarian cancer	0.0002	0.00185	CcSEcCtD
Lidocaine—Hypersensitivity—Chlorambucil—ovarian cancer	0.000198	0.00182	CcSEcCtD
Lidocaine—ABCB1—embryo—ovarian cancer	0.000197	0.0109	CbGeAlD
Lidocaine—Bradycardia—Paclitaxel—ovarian cancer	0.000197	0.00182	CcSEcCtD
Lidocaine—Feeling abnormal—Topotecan—ovarian cancer	0.000197	0.00182	CcSEcCtD
Lidocaine—Skin exfoliation—Doxorubicin—ovarian cancer	0.000194	0.0018	CcSEcCtD
Lidocaine—Haemoglobin—Paclitaxel—ovarian cancer	0.000194	0.00179	CcSEcCtD
Lidocaine—Rhinitis—Paclitaxel—ovarian cancer	0.000194	0.00179	CcSEcCtD
Lidocaine—Haemorrhage—Paclitaxel—ovarian cancer	0.000193	0.00178	CcSEcCtD
Lidocaine—Asthenia—Chlorambucil—ovarian cancer	0.000192	0.00178	CcSEcCtD
Lidocaine—Hypoaesthesia—Paclitaxel—ovarian cancer	0.000192	0.00178	CcSEcCtD
Lidocaine—Neuropathy—Doxorubicin—ovarian cancer	0.000191	0.00177	CcSEcCtD
Lidocaine—Hypotension—Vinorelbine—ovarian cancer	0.000191	0.00176	CcSEcCtD
Lidocaine—Urticaria—Topotecan—ovarian cancer	0.00019	0.00175	CcSEcCtD
Lidocaine—Visual impairment—Paclitaxel—ovarian cancer	0.000186	0.00172	CcSEcCtD
Lidocaine—Coma—Doxorubicin—ovarian cancer	0.000186	0.00172	CcSEcCtD
Lidocaine—Urticaria—Melphalan—ovarian cancer	0.000186	0.00171	CcSEcCtD
Lidocaine—Paraesthesia—Vinorelbine—ovarian cancer	0.000183	0.00169	CcSEcCtD
Lidocaine—Dyspnoea—Vinorelbine—ovarian cancer	0.000182	0.00168	CcSEcCtD
Lidocaine—Eye disorder—Paclitaxel—ovarian cancer	0.000181	0.00167	CcSEcCtD
Lidocaine—CYP2B6—testis—ovarian cancer	0.00018	0.01	CbGeAlD
Lidocaine—Tinnitus—Paclitaxel—ovarian cancer	0.00018	0.00166	CcSEcCtD
Lidocaine—Cardiac disorder—Paclitaxel—ovarian cancer	0.000179	0.00166	CcSEcCtD
Lidocaine—Flushing—Paclitaxel—ovarian cancer	0.000179	0.00166	CcSEcCtD
Lidocaine—Neuropathy peripheral—Docetaxel—ovarian cancer	0.000179	0.00165	CcSEcCtD
Lidocaine—Stomatitis—Docetaxel—ovarian cancer	0.000178	0.00164	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000176	0.00163	CcSEcCtD
Lidocaine—Hypersensitivity—Topotecan—ovarian cancer	0.000176	0.00162	CcSEcCtD
Lidocaine—Angiopathy—Paclitaxel—ovarian cancer	0.000175	0.00162	CcSEcCtD
Lidocaine—Pain—Vinorelbine—ovarian cancer	0.000175	0.00161	CcSEcCtD
Lidocaine—Immune system disorder—Paclitaxel—ovarian cancer	0.000175	0.00161	CcSEcCtD
Lidocaine—Chills—Paclitaxel—ovarian cancer	0.000173	0.0016	CcSEcCtD
Lidocaine—Hypersensitivity—Melphalan—ovarian cancer	0.000172	0.00159	CcSEcCtD
Lidocaine—Asthenia—Topotecan—ovarian cancer	0.000171	0.00158	CcSEcCtD
Lidocaine—Vomiting—Chlorambucil—ovarian cancer	0.00017	0.00157	CcSEcCtD
Lidocaine—CYP3A4—female reproductive system—ovarian cancer	0.000169	0.00938	CbGeAlD
Lidocaine—Erythema—Paclitaxel—ovarian cancer	0.000168	0.00155	CcSEcCtD
Lidocaine—Feeling abnormal—Vinorelbine—ovarian cancer	0.000168	0.00155	CcSEcCtD
Lidocaine—Asthenia—Melphalan—ovarian cancer	0.000168	0.00155	CcSEcCtD
Lidocaine—Dermatitis bullous—Epirubicin—ovarian cancer	0.000167	0.00154	CcSEcCtD
Lidocaine—CYP2D6—female reproductive system—ovarian cancer	0.000166	0.00923	CbGeAlD
Lidocaine—Tension—Paclitaxel—ovarian cancer	0.000165	0.00152	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Epirubicin—ovarian cancer	0.000165	0.00152	CcSEcCtD
Lidocaine—Dysgeusia—Paclitaxel—ovarian cancer	0.000165	0.00152	CcSEcCtD
Lidocaine—Haemoglobin—Docetaxel—ovarian cancer	0.000165	0.00152	CcSEcCtD
Lidocaine—Rhinitis—Docetaxel—ovarian cancer	0.000164	0.00152	CcSEcCtD
Lidocaine—Haemorrhage—Docetaxel—ovarian cancer	0.000164	0.00151	CcSEcCtD
Lidocaine—Nervousness—Paclitaxel—ovarian cancer	0.000163	0.00151	CcSEcCtD
Lidocaine—Hypoaesthesia—Docetaxel—ovarian cancer	0.000163	0.00151	CcSEcCtD
Lidocaine—Back pain—Paclitaxel—ovarian cancer	0.000163	0.0015	CcSEcCtD
Lidocaine—Urticaria—Vinorelbine—ovarian cancer	0.000162	0.0015	CcSEcCtD
Lidocaine—ABCB1—epithelium—ovarian cancer	0.000161	0.00893	CbGeAlD
Lidocaine—Diplopia—Epirubicin—ovarian cancer	0.00016	0.00148	CcSEcCtD
Lidocaine—Osteoarthritis—Epirubicin—ovarian cancer	0.00016	0.00148	CcSEcCtD
Lidocaine—ABCB1—uterine cervix—ovarian cancer	0.00016	0.00886	CbGeAlD
Lidocaine—Nausea—Chlorambucil—ovarian cancer	0.000159	0.00147	CcSEcCtD
Lidocaine—Vision blurred—Paclitaxel—ovarian cancer	0.000159	0.00146	CcSEcCtD
Lidocaine—Visual impairment—Docetaxel—ovarian cancer	0.000158	0.00146	CcSEcCtD
Lidocaine—Dizziness—Topotecan—ovarian cancer	0.000158	0.00146	CcSEcCtD
Lidocaine—Tremor—Paclitaxel—ovarian cancer	0.000158	0.00146	CcSEcCtD
Lidocaine—Dermatitis bullous—Doxorubicin—ovarian cancer	0.000155	0.00143	CcSEcCtD
Lidocaine—Agitation—Paclitaxel—ovarian cancer	0.000155	0.00143	CcSEcCtD
Lidocaine—Angioedema—Paclitaxel—ovarian cancer	0.000154	0.00142	CcSEcCtD
Lidocaine—Eye disorder—Docetaxel—ovarian cancer	0.000153	0.00141	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Doxorubicin—ovarian cancer	0.000153	0.00141	CcSEcCtD
Lidocaine—Cardiac disorder—Docetaxel—ovarian cancer	0.000152	0.0014	CcSEcCtD
Lidocaine—Flushing—Docetaxel—ovarian cancer	0.000152	0.0014	CcSEcCtD
Lidocaine—ABCB1—decidua—ovarian cancer	0.000152	0.00844	CbGeAlD
Lidocaine—Cardiac arrest—Epirubicin—ovarian cancer	0.000152	0.0014	CcSEcCtD
Lidocaine—Vomiting—Topotecan—ovarian cancer	0.000152	0.0014	CcSEcCtD
Lidocaine—CYP2D6—female gonad—ovarian cancer	0.000151	0.0084	CbGeAlD
Lidocaine—SLC22A5—lymph node—ovarian cancer	0.000151	0.00836	CbGeAlD
Lidocaine—Rash—Topotecan—ovarian cancer	0.00015	0.00139	CcSEcCtD
Lidocaine—Hypersensitivity—Vinorelbine—ovarian cancer	0.00015	0.00139	CcSEcCtD
Lidocaine—Dermatitis—Topotecan—ovarian cancer	0.00015	0.00139	CcSEcCtD
Lidocaine—Headache—Topotecan—ovarian cancer	0.00015	0.00138	CcSEcCtD
Lidocaine—Angiopathy—Docetaxel—ovarian cancer	0.000149	0.00137	CcSEcCtD
Lidocaine—Vomiting—Melphalan—ovarian cancer	0.000149	0.00137	CcSEcCtD
Lidocaine—Immune system disorder—Docetaxel—ovarian cancer	0.000148	0.00137	CcSEcCtD
Lidocaine—Loss of consciousness—Paclitaxel—ovarian cancer	0.000148	0.00137	CcSEcCtD
Lidocaine—Osteoarthritis—Doxorubicin—ovarian cancer	0.000148	0.00136	CcSEcCtD
Lidocaine—Diplopia—Doxorubicin—ovarian cancer	0.000148	0.00136	CcSEcCtD
Lidocaine—Rash—Melphalan—ovarian cancer	0.000147	0.00136	CcSEcCtD
Lidocaine—Dermatitis—Melphalan—ovarian cancer	0.000147	0.00136	CcSEcCtD
Lidocaine—Chills—Docetaxel—ovarian cancer	0.000147	0.00136	CcSEcCtD
Lidocaine—Asthenia—Vinorelbine—ovarian cancer	0.000146	0.00135	CcSEcCtD
Lidocaine—Convulsion—Paclitaxel—ovarian cancer	0.000146	0.00135	CcSEcCtD
Lidocaine—Hypertension—Paclitaxel—ovarian cancer	0.000145	0.00134	CcSEcCtD
Lidocaine—ABCB1—endometrium—ovarian cancer	0.000144	0.00801	CbGeAlD
Lidocaine—Chest pain—Paclitaxel—ovarian cancer	0.000143	0.00132	CcSEcCtD
Lidocaine—Anxiety—Paclitaxel—ovarian cancer	0.000143	0.00132	CcSEcCtD
Lidocaine—Erythema—Docetaxel—ovarian cancer	0.000143	0.00132	CcSEcCtD
Lidocaine—Nausea—Topotecan—ovarian cancer	0.000142	0.00131	CcSEcCtD
Lidocaine—Cardiac arrest—Doxorubicin—ovarian cancer	0.000141	0.0013	CcSEcCtD
Lidocaine—Dysgeusia—Docetaxel—ovarian cancer	0.00014	0.00129	CcSEcCtD
Lidocaine—Nausea—Melphalan—ovarian cancer	0.000139	0.00128	CcSEcCtD
Lidocaine—Confusional state—Paclitaxel—ovarian cancer	0.000138	0.00128	CcSEcCtD
Lidocaine—Dysphagia—Epirubicin—ovarian cancer	0.000138	0.00127	CcSEcCtD
Lidocaine—Asthma—Epirubicin—ovarian cancer	0.000138	0.00127	CcSEcCtD
Lidocaine—Back pain—Docetaxel—ovarian cancer	0.000138	0.00127	CcSEcCtD
Lidocaine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000137	0.00127	CcSEcCtD
Lidocaine—Oedema—Paclitaxel—ovarian cancer	0.000137	0.00127	CcSEcCtD
Lidocaine—Shock—Paclitaxel—ovarian cancer	0.000135	0.00125	CcSEcCtD
Lidocaine—Dizziness—Vinorelbine—ovarian cancer	0.000135	0.00125	CcSEcCtD
Lidocaine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000135	0.00124	CcSEcCtD
Lidocaine—CYP2D6—testis—ovarian cancer	0.000134	0.00745	CbGeAlD
Lidocaine—ABCB1—gonad—ovarian cancer	0.000134	0.00743	CbGeAlD
Lidocaine—ABCB1—uterus—ovarian cancer	0.000133	0.00738	CbGeAlD
Lidocaine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000133	0.00123	CcSEcCtD
Lidocaine—Vomiting—Vinorelbine—ovarian cancer	0.00013	0.0012	CcSEcCtD
Lidocaine—Rash—Vinorelbine—ovarian cancer	0.000129	0.00119	CcSEcCtD
Lidocaine—Dermatitis—Vinorelbine—ovarian cancer	0.000129	0.00119	CcSEcCtD
Lidocaine—Hypotension—Paclitaxel—ovarian cancer	0.000128	0.00118	CcSEcCtD
Lidocaine—Headache—Vinorelbine—ovarian cancer	0.000128	0.00118	CcSEcCtD
Lidocaine—Asthma—Doxorubicin—ovarian cancer	0.000128	0.00118	CcSEcCtD
Lidocaine—Dysphagia—Doxorubicin—ovarian cancer	0.000128	0.00118	CcSEcCtD
Lidocaine—Loss of consciousness—Docetaxel—ovarian cancer	0.000125	0.00116	CcSEcCtD
Lidocaine—Convulsion—Docetaxel—ovarian cancer	0.000124	0.00114	CcSEcCtD
Lidocaine—Paraesthesia—Paclitaxel—ovarian cancer	0.000123	0.00114	CcSEcCtD
Lidocaine—Hypertension—Docetaxel—ovarian cancer	0.000123	0.00114	CcSEcCtD
Lidocaine—Drowsiness—Epirubicin—ovarian cancer	0.000123	0.00114	CcSEcCtD
Lidocaine—Dyspnoea—Paclitaxel—ovarian cancer	0.000122	0.00113	CcSEcCtD
Lidocaine—Somnolence—Paclitaxel—ovarian cancer	0.000122	0.00113	CcSEcCtD
Lidocaine—Chest pain—Docetaxel—ovarian cancer	0.000121	0.00112	CcSEcCtD
Lidocaine—Nausea—Vinorelbine—ovarian cancer	0.000121	0.00112	CcSEcCtD
Lidocaine—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000121	0.00111	CcSEcCtD
Lidocaine—Stomatitis—Epirubicin—ovarian cancer	0.00012	0.00111	CcSEcCtD
Lidocaine—ABCB1—female reproductive system—ovarian cancer	0.00012	0.00664	CbGeAlD
Lidocaine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000119	0.00109	CcSEcCtD
Lidocaine—Pain—Paclitaxel—ovarian cancer	0.000117	0.00108	CcSEcCtD
Lidocaine—Confusional state—Docetaxel—ovarian cancer	0.000117	0.00108	CcSEcCtD
Lidocaine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000116	0.00107	CcSEcCtD
Lidocaine—Oedema—Docetaxel—ovarian cancer	0.000116	0.00107	CcSEcCtD
Lidocaine—Shock—Docetaxel—ovarian cancer	0.000115	0.00106	CcSEcCtD
Lidocaine—Nervous system disorder—Docetaxel—ovarian cancer	0.000114	0.00105	CcSEcCtD
Lidocaine—Drowsiness—Doxorubicin—ovarian cancer	0.000114	0.00105	CcSEcCtD
Lidocaine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000113	0.00104	CcSEcCtD
Lidocaine—ABCB1—bone marrow—ovarian cancer	0.000113	0.00627	CbGeAlD
Lidocaine—Bradycardia—Epirubicin—ovarian cancer	0.000113	0.00104	CcSEcCtD
Lidocaine—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000112	0.00103	CcSEcCtD
Lidocaine—Haemoglobin—Epirubicin—ovarian cancer	0.000111	0.00103	CcSEcCtD
Lidocaine—Stomatitis—Doxorubicin—ovarian cancer	0.000111	0.00103	CcSEcCtD
Lidocaine—Rhinitis—Epirubicin—ovarian cancer	0.000111	0.00102	CcSEcCtD
Lidocaine—Haemorrhage—Epirubicin—ovarian cancer	0.000111	0.00102	CcSEcCtD
Lidocaine—Hypoaesthesia—Epirubicin—ovarian cancer	0.00011	0.00102	CcSEcCtD
Lidocaine—Urticaria—Paclitaxel—ovarian cancer	0.000109	0.00101	CcSEcCtD
Lidocaine—ABCB1—female gonad—ovarian cancer	0.000109	0.00604	CbGeAlD
Lidocaine—Hypotension—Docetaxel—ovarian cancer	0.000109	0.001	CcSEcCtD
Lidocaine—ABCB1—vagina—ovarian cancer	0.000108	0.006	CbGeAlD
Lidocaine—Visual impairment—Epirubicin—ovarian cancer	0.000106	0.000983	CcSEcCtD
Lidocaine—Paraesthesia—Docetaxel—ovarian cancer	0.000105	0.000965	CcSEcCtD
Lidocaine—Bradycardia—Doxorubicin—ovarian cancer	0.000104	0.000961	CcSEcCtD
Lidocaine—Dyspnoea—Docetaxel—ovarian cancer	0.000104	0.000958	CcSEcCtD
Lidocaine—Somnolence—Docetaxel—ovarian cancer	0.000103	0.000956	CcSEcCtD
Lidocaine—Eye disorder—Epirubicin—ovarian cancer	0.000103	0.000954	CcSEcCtD
Lidocaine—Tinnitus—Epirubicin—ovarian cancer	0.000103	0.000951	CcSEcCtD
Lidocaine—Haemoglobin—Doxorubicin—ovarian cancer	0.000103	0.000949	CcSEcCtD
Lidocaine—Cardiac disorder—Epirubicin—ovarian cancer	0.000103	0.000947	CcSEcCtD
Lidocaine—Flushing—Epirubicin—ovarian cancer	0.000103	0.000947	CcSEcCtD
Lidocaine—Rhinitis—Doxorubicin—ovarian cancer	0.000103	0.000947	CcSEcCtD
Lidocaine—Haemorrhage—Doxorubicin—ovarian cancer	0.000102	0.000944	CcSEcCtD
Lidocaine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000102	0.000939	CcSEcCtD
Lidocaine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000101	0.000934	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.0001	0.000928	CcSEcCtD
Lidocaine—Angiopathy—Epirubicin—ovarian cancer	0.0001	0.000926	CcSEcCtD
Lidocaine—Immune system disorder—Epirubicin—ovarian cancer	9.98e-05	0.000922	CcSEcCtD
Lidocaine—Pain—Docetaxel—ovarian cancer	9.95e-05	0.000919	CcSEcCtD
Lidocaine—Chills—Epirubicin—ovarian cancer	9.92e-05	0.000916	CcSEcCtD
Lidocaine—Visual impairment—Doxorubicin—ovarian cancer	9.85e-05	0.00091	CcSEcCtD
Lidocaine—Asthenia—Paclitaxel—ovarian cancer	9.85e-05	0.00091	CcSEcCtD
Lidocaine—ABCB1—testis—ovarian cancer	9.65e-05	0.00536	CbGeAlD
Lidocaine—Erythema—Epirubicin—ovarian cancer	9.62e-05	0.000888	CcSEcCtD
Lidocaine—Feeling abnormal—Docetaxel—ovarian cancer	9.59e-05	0.000886	CcSEcCtD
Lidocaine—Eye disorder—Doxorubicin—ovarian cancer	9.56e-05	0.000882	CcSEcCtD
Lidocaine—Tinnitus—Doxorubicin—ovarian cancer	9.53e-05	0.00088	CcSEcCtD
Lidocaine—Cardiac disorder—Doxorubicin—ovarian cancer	9.49e-05	0.000876	CcSEcCtD
Lidocaine—Flushing—Doxorubicin—ovarian cancer	9.49e-05	0.000876	CcSEcCtD
Lidocaine—Tension—Epirubicin—ovarian cancer	9.44e-05	0.000872	CcSEcCtD
Lidocaine—Dysgeusia—Epirubicin—ovarian cancer	9.42e-05	0.00087	CcSEcCtD
Lidocaine—Nervousness—Epirubicin—ovarian cancer	9.34e-05	0.000863	CcSEcCtD
Lidocaine—Back pain—Epirubicin—ovarian cancer	9.31e-05	0.000859	CcSEcCtD
Lidocaine—Angiopathy—Doxorubicin—ovarian cancer	9.28e-05	0.000857	CcSEcCtD
Lidocaine—Immune system disorder—Doxorubicin—ovarian cancer	9.24e-05	0.000853	CcSEcCtD
Lidocaine—Chills—Doxorubicin—ovarian cancer	9.17e-05	0.000847	CcSEcCtD
Lidocaine—Dizziness—Paclitaxel—ovarian cancer	9.08e-05	0.000839	CcSEcCtD
Lidocaine—Vision blurred—Epirubicin—ovarian cancer	9.07e-05	0.000837	CcSEcCtD
Lidocaine—Erythema—Doxorubicin—ovarian cancer	8.9e-05	0.000822	CcSEcCtD
Lidocaine—Agitation—Epirubicin—ovarian cancer	8.84e-05	0.000816	CcSEcCtD
Lidocaine—Tension—Doxorubicin—ovarian cancer	8.73e-05	0.000807	CcSEcCtD
Lidocaine—Vomiting—Paclitaxel—ovarian cancer	8.73e-05	0.000806	CcSEcCtD
Lidocaine—Dysgeusia—Doxorubicin—ovarian cancer	8.72e-05	0.000805	CcSEcCtD
Lidocaine—Rash—Paclitaxel—ovarian cancer	8.66e-05	0.0008	CcSEcCtD
Lidocaine—Dermatitis—Paclitaxel—ovarian cancer	8.65e-05	0.000799	CcSEcCtD
Lidocaine—Nervousness—Doxorubicin—ovarian cancer	8.65e-05	0.000798	CcSEcCtD
Lidocaine—Back pain—Doxorubicin—ovarian cancer	8.61e-05	0.000795	CcSEcCtD
Lidocaine—Headache—Paclitaxel—ovarian cancer	8.6e-05	0.000794	CcSEcCtD
Lidocaine—Hypersensitivity—Docetaxel—ovarian cancer	8.58e-05	0.000792	CcSEcCtD
Lidocaine—Loss of consciousness—Epirubicin—ovarian cancer	8.46e-05	0.000781	CcSEcCtD
Lidocaine—Vision blurred—Doxorubicin—ovarian cancer	8.39e-05	0.000775	CcSEcCtD
Lidocaine—Asthenia—Docetaxel—ovarian cancer	8.35e-05	0.000771	CcSEcCtD
Lidocaine—Convulsion—Epirubicin—ovarian cancer	8.34e-05	0.00077	CcSEcCtD
Lidocaine—Hypertension—Epirubicin—ovarian cancer	8.31e-05	0.000767	CcSEcCtD
Lidocaine—Chest pain—Epirubicin—ovarian cancer	8.19e-05	0.000756	CcSEcCtD
Lidocaine—Agitation—Doxorubicin—ovarian cancer	8.18e-05	0.000755	CcSEcCtD
Lidocaine—Anxiety—Epirubicin—ovarian cancer	8.16e-05	0.000754	CcSEcCtD
Lidocaine—Nausea—Paclitaxel—ovarian cancer	8.16e-05	0.000753	CcSEcCtD
Lidocaine—Confusional state—Epirubicin—ovarian cancer	7.92e-05	0.000731	CcSEcCtD
Lidocaine—Anaphylactic shock—Epirubicin—ovarian cancer	7.85e-05	0.000725	CcSEcCtD
Lidocaine—Oedema—Epirubicin—ovarian cancer	7.85e-05	0.000725	CcSEcCtD
Lidocaine—Loss of consciousness—Doxorubicin—ovarian cancer	7.82e-05	0.000722	CcSEcCtD
Lidocaine—Shock—Epirubicin—ovarian cancer	7.72e-05	0.000713	CcSEcCtD
Lidocaine—Convulsion—Doxorubicin—ovarian cancer	7.71e-05	0.000712	CcSEcCtD
Lidocaine—Nervous system disorder—Epirubicin—ovarian cancer	7.7e-05	0.000711	CcSEcCtD
Lidocaine—Dizziness—Docetaxel—ovarian cancer	7.7e-05	0.000711	CcSEcCtD
Lidocaine—Hypertension—Doxorubicin—ovarian cancer	7.69e-05	0.00071	CcSEcCtD
Lidocaine—Hyperhidrosis—Epirubicin—ovarian cancer	7.59e-05	0.000701	CcSEcCtD
Lidocaine—Chest pain—Doxorubicin—ovarian cancer	7.58e-05	0.0007	CcSEcCtD
Lidocaine—Anxiety—Doxorubicin—ovarian cancer	7.55e-05	0.000697	CcSEcCtD
Lidocaine—Vomiting—Docetaxel—ovarian cancer	7.4e-05	0.000683	CcSEcCtD
Lidocaine—Rash—Docetaxel—ovarian cancer	7.34e-05	0.000678	CcSEcCtD
Lidocaine—Hypotension—Epirubicin—ovarian cancer	7.34e-05	0.000677	CcSEcCtD
Lidocaine—Dermatitis—Docetaxel—ovarian cancer	7.33e-05	0.000677	CcSEcCtD
Lidocaine—Confusional state—Doxorubicin—ovarian cancer	7.33e-05	0.000676	CcSEcCtD
Lidocaine—Headache—Docetaxel—ovarian cancer	7.29e-05	0.000673	CcSEcCtD
Lidocaine—Anaphylactic shock—Doxorubicin—ovarian cancer	7.26e-05	0.000671	CcSEcCtD
Lidocaine—Oedema—Doxorubicin—ovarian cancer	7.26e-05	0.000671	CcSEcCtD
Lidocaine—Shock—Doxorubicin—ovarian cancer	7.15e-05	0.00066	CcSEcCtD
Lidocaine—Nervous system disorder—Doxorubicin—ovarian cancer	7.12e-05	0.000658	CcSEcCtD
Lidocaine—Paraesthesia—Epirubicin—ovarian cancer	7.05e-05	0.000651	CcSEcCtD
Lidocaine—Hyperhidrosis—Doxorubicin—ovarian cancer	7.02e-05	0.000648	CcSEcCtD
Lidocaine—Dyspnoea—Epirubicin—ovarian cancer	7e-05	0.000646	CcSEcCtD
Lidocaine—ABCB1—lymph node—ovarian cancer	6.99e-05	0.00388	CbGeAlD
Lidocaine—Somnolence—Epirubicin—ovarian cancer	6.98e-05	0.000645	CcSEcCtD
Lidocaine—Nausea—Docetaxel—ovarian cancer	6.91e-05	0.000638	CcSEcCtD
Lidocaine—Hypotension—Doxorubicin—ovarian cancer	6.79e-05	0.000627	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Epirubicin—ovarian cancer	6.78e-05	0.000626	CcSEcCtD
Lidocaine—Pain—Epirubicin—ovarian cancer	6.71e-05	0.00062	CcSEcCtD
Lidocaine—Paraesthesia—Doxorubicin—ovarian cancer	6.52e-05	0.000602	CcSEcCtD
Lidocaine—Dyspnoea—Doxorubicin—ovarian cancer	6.48e-05	0.000598	CcSEcCtD
Lidocaine—Feeling abnormal—Epirubicin—ovarian cancer	6.47e-05	0.000597	CcSEcCtD
Lidocaine—Somnolence—Doxorubicin—ovarian cancer	6.46e-05	0.000596	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	6.27e-05	0.000579	CcSEcCtD
Lidocaine—Urticaria—Epirubicin—ovarian cancer	6.24e-05	0.000576	CcSEcCtD
Lidocaine—Pain—Doxorubicin—ovarian cancer	6.21e-05	0.000574	CcSEcCtD
Lidocaine—Feeling abnormal—Doxorubicin—ovarian cancer	5.99e-05	0.000553	CcSEcCtD
Lidocaine—Hypersensitivity—Epirubicin—ovarian cancer	5.78e-05	0.000534	CcSEcCtD
Lidocaine—Urticaria—Doxorubicin—ovarian cancer	5.77e-05	0.000533	CcSEcCtD
Lidocaine—Asthenia—Epirubicin—ovarian cancer	5.63e-05	0.00052	CcSEcCtD
Lidocaine—Hypersensitivity—Doxorubicin—ovarian cancer	5.35e-05	0.000494	CcSEcCtD
Lidocaine—Asthenia—Doxorubicin—ovarian cancer	5.21e-05	0.000481	CcSEcCtD
Lidocaine—Dizziness—Epirubicin—ovarian cancer	5.19e-05	0.000479	CcSEcCtD
Lidocaine—Vomiting—Epirubicin—ovarian cancer	4.99e-05	0.000461	CcSEcCtD
Lidocaine—Rash—Epirubicin—ovarian cancer	4.95e-05	0.000457	CcSEcCtD
Lidocaine—Dermatitis—Epirubicin—ovarian cancer	4.95e-05	0.000457	CcSEcCtD
Lidocaine—Headache—Epirubicin—ovarian cancer	4.92e-05	0.000454	CcSEcCtD
Lidocaine—Dizziness—Doxorubicin—ovarian cancer	4.8e-05	0.000444	CcSEcCtD
Lidocaine—Nausea—Epirubicin—ovarian cancer	4.66e-05	0.000431	CcSEcCtD
Lidocaine—Vomiting—Doxorubicin—ovarian cancer	4.62e-05	0.000427	CcSEcCtD
Lidocaine—Rash—Doxorubicin—ovarian cancer	4.58e-05	0.000423	CcSEcCtD
Lidocaine—Dermatitis—Doxorubicin—ovarian cancer	4.58e-05	0.000423	CcSEcCtD
Lidocaine—Headache—Doxorubicin—ovarian cancer	4.55e-05	0.00042	CcSEcCtD
Lidocaine—Nausea—Doxorubicin—ovarian cancer	4.32e-05	0.000398	CcSEcCtD
Lidocaine—EGFR—Signaling Pathways—PPP2R1A—ovarian cancer	8.53e-06	0.000123	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—SLC5A5—ovarian cancer	8.5e-06	0.000123	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PIK3CD—ovarian cancer	8.49e-06	0.000123	CbGpPWpGaD
Lidocaine—EGFR—Disease—IL6ST—ovarian cancer	8.48e-06	0.000123	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—FASN—ovarian cancer	8.45e-06	0.000122	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	8.37e-06	0.000121	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PIK3CD—ovarian cancer	8.35e-06	0.000121	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—SLC5A5—ovarian cancer	8.31e-06	0.00012	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYTB—ovarian cancer	8.22e-06	0.000119	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—SLC2A1—ovarian cancer	8.21e-06	0.000119	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—MAPK1—ovarian cancer	8.16e-06	0.000118	CbGpPWpGaD
Lidocaine—EGFR—Disease—APC—ovarian cancer	8.15e-06	0.000118	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CDH1—ovarian cancer	8.12e-06	0.000117	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—ABCB1—ovarian cancer	8.03e-06	0.000116	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—SLC2A1—ovarian cancer	8.02e-06	0.000116	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	7.93e-06	0.000115	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—TYMS—ovarian cancer	7.89e-06	0.000114	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CYP1B1—ovarian cancer	7.87e-06	0.000114	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—YAP1—ovarian cancer	7.82e-06	0.000113	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.81e-06	0.000113	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PIK3CD—ovarian cancer	7.76e-06	0.000112	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—KRAS—ovarian cancer	7.71e-06	0.000111	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CYP1B1—ovarian cancer	7.69e-06	0.000111	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—HRAS—ovarian cancer	7.42e-06	0.000107	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PIK3CB—ovarian cancer	7.4e-06	0.000107	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—KRAS—ovarian cancer	7.4e-06	0.000107	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—YAP1—ovarian cancer	7.37e-06	0.000106	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—FASN—ovarian cancer	7.32e-06	0.000106	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—YAP1—ovarian cancer	7.3e-06	0.000106	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PIK3CB—ovarian cancer	7.28e-06	0.000105	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	7.23e-06	0.000104	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—SLC5A5—ovarian cancer	7.2e-06	0.000104	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PPP1CC—ovarian cancer	7.18e-06	0.000104	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—BRIP1—ovarian cancer	7.18e-06	0.000104	CbGpPWpGaD
Lidocaine—EGFR—Disease—PIK3CD—ovarian cancer	7.17e-06	0.000104	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CXCL8—ovarian cancer	7.11e-06	0.000103	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—IL6—ovarian cancer	7.1e-06	0.000103	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—PIK3CA—ovarian cancer	7.08e-06	0.000102	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	7.07e-06	0.000102	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PPP2R1A—ovarian cancer	6.98e-06	0.000101	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—SLC2A1—ovarian cancer	6.95e-06	0.0001	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—CAV1—ovarian cancer	6.93e-06	0.0001	CbGpPWpGaD
Lidocaine—EGFR—Immune System—ERBB2—ovarian cancer	6.85e-06	9.91e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	6.82e-06	9.86e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.8e-06	9.84e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—IL2—ovarian cancer	6.8e-06	9.83e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—PIK3CA—ovarian cancer	6.8e-06	9.83e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.78e-06	9.8e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TERT—ovarian cancer	6.77e-06	9.79e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—MTOR—ovarian cancer	6.76e-06	9.78e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PIK3CB—ovarian cancer	6.76e-06	9.78e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CYP1B1—ovarian cancer	6.66e-06	9.63e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—HRAS—ovarian cancer	6.55e-06	9.47e-05	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—AKT1—ovarian cancer	6.55e-06	9.47e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—ABCB1—ovarian cancer	6.48e-06	9.37e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—FASN—ovarian cancer	6.37e-06	9.21e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—TYMS—ovarian cancer	6.36e-06	9.2e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—CAV1—ovarian cancer	6.36e-06	9.19e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	6.35e-06	9.18e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CDKN1B—ovarian cancer	6.35e-06	9.18e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ABCB1—ovarian cancer	6.33e-06	9.16e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—ERBB2—ovarian cancer	6.33e-06	9.15e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CG—ovarian cancer	6.32e-06	9.13e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTEN—ovarian cancer	6.29e-06	9.09e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—HRAS—ovarian cancer	6.29e-06	9.09e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—IL6—ovarian cancer	6.27e-06	9.06e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—SLC5A5—ovarian cancer	6.27e-06	9.06e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CAV1—ovarian cancer	6.27e-06	9.06e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PIK3CB—ovarian cancer	6.25e-06	9.03e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MTOR—ovarian cancer	6.25e-06	9.03e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—YAP1—ovarian cancer	6.24e-06	9.02e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—TYMS—ovarian cancer	6.22e-06	8.99e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL2—ovarian cancer	6.21e-06	8.98e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.18e-06	8.93e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—SLC2A1—ovarian cancer	6.05e-06	8.75e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—ESR1—ovarian cancer	6.04e-06	8.73e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—FASN—ovarian cancer	6.01e-06	8.68e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CTNNB1—ovarian cancer	6e-06	8.67e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—FASN—ovarian cancer	5.95e-06	8.61e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL6ST—ovarian cancer	5.94e-06	8.59e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	5.91e-06	8.54e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—SLC5A5—ovarian cancer	5.91e-06	8.54e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.88e-06	8.5e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CDKN1B—ovarian cancer	5.86e-06	8.47e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—SLC5A5—ovarian cancer	5.86e-06	8.47e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PTEN—ovarian cancer	5.85e-06	8.45e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CYP1B1—ovarian cancer	5.8e-06	8.39e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CG—ovarian cancer	5.79e-06	8.37e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—AKT1—ovarian cancer	5.78e-06	8.36e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CG—ovarian cancer	5.71e-06	8.25e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—APC—ovarian cancer	5.71e-06	8.25e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—NRAS—ovarian cancer	5.71e-06	8.25e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—SLC2A1—ovarian cancer	5.71e-06	8.25e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—SLC2A1—ovarian cancer	5.66e-06	8.18e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—AKT1—ovarian cancer	5.55e-06	8.03e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CD—ovarian cancer	5.55e-06	8.03e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.54e-06	8.01e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CTNNB1—ovarian cancer	5.54e-06	8e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ABCB1—ovarian cancer	5.49e-06	7.93e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	5.47e-06	7.91e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—MAPK3—ovarian cancer	5.47e-06	7.9e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.43e-06	7.85e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CYP1B1—ovarian cancer	5.42e-06	7.84e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTEN—ovarian cancer	5.4e-06	7.8e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—TYMS—ovarian cancer	5.39e-06	7.79e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—STAT3—ovarian cancer	5.23e-06	7.56e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—NRAS—ovarian cancer	5.22e-06	7.54e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—MAPK1—ovarian cancer	5.2e-06	7.52e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PPP2R1A—ovarian cancer	5.15e-06	7.44e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CAV1—ovarian cancer	5.13e-06	7.41e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CD—ovarian cancer	5.09e-06	7.36e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—FASN—ovarian cancer	5.09e-06	7.35e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CD—ovarian cancer	5.02e-06	7.25e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CAV1—ovarian cancer	5.01e-06	7.25e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—SLC5A5—ovarian cancer	5e-06	7.23e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—MAPK3—ovarian cancer	4.99e-06	7.22e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—KRAS—ovarian cancer	4.91e-06	7.1e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	4.85e-06	7.01e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CB—ovarian cancer	4.84e-06	7e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—SLC2A1—ovarian cancer	4.83e-06	6.99e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—STAT3—ovarian cancer	4.83e-06	6.98e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—YAP1—ovarian cancer	4.82e-06	6.96e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—NRAS—ovarian cancer	4.82e-06	6.96e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	4.81e-06	6.95e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.79e-06	6.92e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—MAPK1—ovarian cancer	4.75e-06	6.87e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.73e-06	6.84e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—TYMS—ovarian cancer	4.69e-06	6.79e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CG—ovarian cancer	4.67e-06	6.75e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYP1B1—ovarian cancer	4.63e-06	6.7e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MAPK3—ovarian cancer	4.61e-06	6.67e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CG—ovarian cancer	4.57e-06	6.6e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PIK3CA—ovarian cancer	4.51e-06	6.52e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ABCB1—ovarian cancer	4.5e-06	6.51e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—KRAS—ovarian cancer	4.49e-06	6.49e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MYC—ovarian cancer	4.49e-06	6.48e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ABCB1—ovarian cancer	4.47e-06	6.45e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PIK3CA—ovarian cancer	4.44e-06	6.42e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CB—ovarian cancer	4.44e-06	6.41e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—ERBB2—ovarian cancer	4.43e-06	6.41e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—TYMS—ovarian cancer	4.42e-06	6.39e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MAPK1—ovarian cancer	4.39e-06	6.34e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—TYMS—ovarian cancer	4.39e-06	6.34e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CB—ovarian cancer	4.37e-06	6.32e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MTOR—ovarian cancer	4.37e-06	6.32e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CAV1—ovarian cancer	4.34e-06	6.28e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CXCL8—ovarian cancer	4.2e-06	6.08e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTEN—ovarian cancer	4.18e-06	6.05e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—HRAS—ovarian cancer	4.18e-06	6.04e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.15e-06	6e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—KRAS—ovarian cancer	4.14e-06	5.99e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PIK3CA—ovarian cancer	4.12e-06	5.96e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	4.11e-06	5.94e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CD—ovarian cancer	4.11e-06	5.94e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CDKN1B—ovarian cancer	4.1e-06	5.93e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.09e-06	5.91e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CASP3—ovarian cancer	4.02e-06	5.82e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL2—ovarian cancer	4.02e-06	5.81e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CD—ovarian cancer	4.01e-06	5.8e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—IL6—ovarian cancer	4e-06	5.78e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CG—ovarian cancer	3.95e-06	5.72e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—FASN—ovarian cancer	3.93e-06	5.68e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCND1—ovarian cancer	3.92e-06	5.66e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CTNNB1—ovarian cancer	3.88e-06	5.61e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—SLC5A5—ovarian cancer	3.86e-06	5.58e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTEN—ovarian cancer	3.83e-06	5.54e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ABCB1—ovarian cancer	3.82e-06	5.52e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HRAS—ovarian cancer	3.82e-06	5.52e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PIK3CA—ovarian cancer	3.81e-06	5.5e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MMP9—ovarian cancer	3.8e-06	5.5e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CAV1—ovarian cancer	3.78e-06	5.47e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PTEN—ovarian cancer	3.78e-06	5.46e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—TYMS—ovarian cancer	3.75e-06	5.42e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—SLC2A1—ovarian cancer	3.73e-06	5.39e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—AKT1—ovarian cancer	3.69e-06	5.33e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL6—ovarian cancer	3.65e-06	5.28e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—AKT1—ovarian cancer	3.63e-06	5.24e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CB—ovarian cancer	3.58e-06	5.17e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP1B1—ovarian cancer	3.58e-06	5.17e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CAV1—ovarian cancer	3.56e-06	5.15e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CAV1—ovarian cancer	3.53e-06	5.11e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—HRAS—ovarian cancer	3.52e-06	5.09e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CB—ovarian cancer	3.5e-06	5.06e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CD—ovarian cancer	3.48e-06	5.03e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CG—ovarian cancer	3.45e-06	4.98e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—VEGFA—ovarian cancer	3.41e-06	4.93e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—STAT3—ovarian cancer	3.38e-06	4.89e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.38e-06	4.88e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NRAS—ovarian cancer	3.37e-06	4.87e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—IL6—ovarian cancer	3.37e-06	4.87e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—AKT1—ovarian cancer	3.37e-06	4.87e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	3.25e-06	4.69e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MAPK3—ovarian cancer	3.23e-06	4.67e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CG—ovarian cancer	3.22e-06	4.65e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	3.17e-06	4.58e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MYC—ovarian cancer	3.14e-06	4.54e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—AKT1—ovarian cancer	3.11e-06	4.5e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTEN—ovarian cancer	3.09e-06	4.47e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MAPK1—ovarian cancer	3.07e-06	4.44e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CB—ovarian cancer	3.03e-06	4.38e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CD—ovarian cancer	3.03e-06	4.38e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTEN—ovarian cancer	3.02e-06	4.37e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CAV1—ovarian cancer	3.02e-06	4.37e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CA—ovarian cancer	2.95e-06	4.27e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.94e-06	4.26e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KRAS—ovarian cancer	2.9e-06	4.2e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—TYMS—ovarian cancer	2.89e-06	4.18e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.88e-06	4.17e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	2.85e-06	4.13e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CD—ovarian cancer	2.83e-06	4.09e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	2.75e-06	3.98e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CA—ovarian cancer	2.7e-06	3.91e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CA—ovarian cancer	2.67e-06	3.85e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.64e-06	3.82e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTEN—ovarian cancer	2.62e-06	3.79e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TP53—ovarian cancer	2.58e-06	3.73e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	2.49e-06	3.6e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—HRAS—ovarian cancer	2.47e-06	3.57e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CB—ovarian cancer	2.47e-06	3.57e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	2.42e-06	3.5e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—AKT1—ovarian cancer	2.41e-06	3.48e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL6—ovarian cancer	2.36e-06	3.41e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CAV1—ovarian cancer	2.33e-06	3.37e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTEN—ovarian cancer	2.28e-06	3.3e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—AKT1—ovarian cancer	2.21e-06	3.19e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CA—ovarian cancer	2.18e-06	3.15e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—AKT1—ovarian cancer	2.18e-06	3.15e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTEN—ovarian cancer	2.15e-06	3.11e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CA—ovarian cancer	2.13e-06	3.08e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTEN—ovarian cancer	2.13e-06	3.08e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.12e-06	3.07e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	2.11e-06	3.05e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.87e-06	2.7e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CA—ovarian cancer	1.85e-06	2.67e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTEN—ovarian cancer	1.82e-06	2.63e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—AKT1—ovarian cancer	1.78e-06	2.58e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—AKT1—ovarian cancer	1.74e-06	2.52e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.63e-06	2.35e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.61e-06	2.33e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.52e-06	2.19e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—AKT1—ovarian cancer	1.51e-06	2.18e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.5e-06	2.17e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTEN—ovarian cancer	1.41e-06	2.03e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—AKT1—ovarian cancer	1.31e-06	1.9e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.28e-06	1.86e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—AKT1—ovarian cancer	1.24e-06	1.79e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—AKT1—ovarian cancer	1.23e-06	1.78e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—AKT1—ovarian cancer	1.05e-06	1.52e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	9.92e-07	1.43e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—AKT1—ovarian cancer	8.1e-07	1.17e-05	CbGpPWpGaD
